Seth A Rosenthal1, Daniel Hunt2, A Oliver Sartor3, Kenneth J Pienta4, Leonard Gomella5, David Grignon6, Raghu Rajan7, Kevin J Kerlin8, Christopher U Jones9, Michael Dobelbower10, William U Shipley11, Kenneth Zeitzer12, Daniel A Hamstra13, Viroon Donavanik14, Marvin Rotman15, Alan C Hartford16, Jeffrey Michalski17, Michael Seider18, Harold Kim19, Deborah A Kuban20, Jennifer Moughan2, Howard Sandler21. 1. Radiation Oncology, Sutter Cancer Centers, Roseville, California. Electronic address: rosents@sutterhealth.org. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. 3. Tulane University Medical Center, New Orleans, Louisiana. 4. Johns Hopkins School of Medicine, Baltimore, Maryland. 5. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 6. Indiana University, Bloomington, Indiana. 7. McGill University, Montreal, Quebec, Canada. 8. Community Clinical Oncology Program, Southeast Cancer Control Consortium, Inc, Winston-Salem, North Carolina. 9. Radiation Oncology, Sutter Cancer Centers, Roseville, California; Radiological Associates of Sacramento, Sacramento, California. 10. University of Alabama at Birmingham Medical Center, Birmingham, Alabama. 11. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 12. Albert Einstein Medical Center, Bronx, New York. 13. University of Michigan Medical Center, Ann Arbor, Michigan. 14. Christiana Care Health Services, Inc, Wilmington, Delaware. 15. State University of New York Health Science Center-Brooklyn, Brooklyn, New York. 16. Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire. 17. Washington University, St. Louis, Missouri. 18. Akron City Hospital, Akron, Ohio. 19. Wayne State University, Detroit, Michigan. 20. University of Texas MD Anderson Cancer Center, Houston, Texas. 21. Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
PURPOSE:Long-term (LT) androgen suppression (AS) with radiation therapy (RT) is a standard treatment of high-risk, localized prostate cancer (PCa). Radiation Therapy Oncology Group 9902 was a randomized trial testing the hypothesis that adjuvant combination chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide plus LT AS plus RT would improve overall survival (OS). METHODS AND MATERIALS: Patients with high-risk PCa (prostate-specific antigen 20-100 ng/mL and Gleason score [GS] ≥ 7 or clinical stage ≥ T2 and GS ≥ 8) were randomized to RT and AS (AS + RT) alone or with adjuvant CT (AS + RT + CT). CT was given as four 21-day cycles, delivered beginning 28 days after 70.2 Gy of RT. AS was given as luteinizing hormone-releasing hormone for 24 months, beginning 2 months before RT plus an oral antiandrogen for 4 months before and during RT. The study was designed based on a 6% improvement in OS from 79% to 85% at 5 years, with 90% power and a 2-sided alpha of 0.05. RESULTS: A total of 397 patients (380 eligible) were randomized. The patients had high-risk PCa, 68% with GS 8 to 10 and 34% T3 to T4 tumors, and median prostate-specific antigen of 22.6 ng/mL. The median follow-up period was 9.2 years. The trial closed early because of excess thromboembolic toxicity in the CT arm. The 10-year results for all randomized patients revealed no significant difference between the AS + RT and AS + RT + CT arms in OS (65% vs 63%; P=.81), biochemical failure (58% vs 54%; P=.82), local progression (11% vs 7%; P=.09), distant metastases (16% vs 14%; P=.42), or disease-free survival (22% vs 26%; P=.61). CONCLUSIONS: NRG Oncology RTOG 9902 showed no significant differences in OS, biochemical failure, local progression, distant metastases, or disease-free survival with the addition of adjuvant CT to LT AS + RT. The trial results provide valuable data regarding the natural history of high-risk PCa treated with LT AS + RT and have implications for the feasibility of clinical trial accrual and tolerability using CT for PCa.
RCT Entities:
PURPOSE: Long-term (LT) androgen suppression (AS) with radiation therapy (RT) is a standard treatment of high-risk, localized prostate cancer (PCa). Radiation Therapy Oncology Group 9902 was a randomized trial testing the hypothesis that adjuvant combination chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide plus LT AS plus RT would improve overall survival (OS). METHODS AND MATERIALS: Patients with high-risk PCa (prostate-specific antigen 20-100 ng/mL and Gleason score [GS] ≥ 7 or clinical stage ≥ T2 and GS ≥ 8) were randomized to RT and AS (AS + RT) alone or with adjuvant CT (AS + RT + CT). CT was given as four 21-day cycles, delivered beginning 28 days after 70.2 Gy of RT. AS was given as luteinizing hormone-releasing hormone for 24 months, beginning 2 months before RT plus an oral antiandrogen for 4 months before and during RT. The study was designed based on a 6% improvement in OS from 79% to 85% at 5 years, with 90% power and a 2-sided alpha of 0.05. RESULTS: A total of 397 patients (380 eligible) were randomized. The patients had high-risk PCa, 68% with GS 8 to 10 and 34% T3 to T4 tumors, and median prostate-specific antigen of 22.6 ng/mL. The median follow-up period was 9.2 years. The trial closed early because of excess thromboembolic toxicity in the CT arm. The 10-year results for all randomized patients revealed no significant difference between the AS + RT and AS + RT + CT arms in OS (65% vs 63%; P=.81), biochemical failure (58% vs 54%; P=.82), local progression (11% vs 7%; P=.09), distant metastases (16% vs 14%; P=.42), or disease-free survival (22% vs 26%; P=.61). CONCLUSIONS: NRG Oncology RTOG 9902 showed no significant differences in OS, biochemical failure, local progression, distant metastases, or disease-free survival with the addition of adjuvant CT to LT AS + RT. The trial results provide valuable data regarding the natural history of high-risk PCa treated with LT AS + RT and have implications for the feasibility of clinical trial accrual and tolerability using CT for PCa.
Authors: Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley Journal: N Engl J Med Date: 2011-07-14 Impact factor: 91.245
Authors: Srikala S Sridhar; Stephen J Freedland; Martin E Gleave; Celestia Higano; Peter Mulders; Chris Parker; Oliver Sartor; Fred Saad Journal: Eur Urol Date: 2013-08-11 Impact factor: 20.096
Authors: M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart Journal: N Engl J Med Date: 1997-07-31 Impact factor: 91.245
Authors: Thomas M Pisansky; Daniel Hunt; Leonard G Gomella; Mahul B Amin; Alexander G Balogh; Daniel M Chinn; Michael J Seider; Marie Duclos; Seth A Rosenthal; Glenn S Bauman; Elizabeth M Gore; Marvin Z Rotman; Himanshu R Lukka; William U Shipley; James J Dignam; Howard M Sandler Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544
Authors: Kevin Shee; Claire M de la Calle; Albert J Chang; Anthony C Wong; Felix Y Feng; Alexander R Gottschalk; Peter R Carroll; Hao G Nguyen Journal: Adv Radiat Oncol Date: 2022-03-12
Authors: Daniel A Hamstra; Stephanie L Pugh; Herbert Lepor; Seth A Rosenthal; Kenneth J Pienta; Leonard Gomella; Christopher Peters; David Paul D'Souza; Kenneth L Zeitzer; Christopher U Jones; William A Hall; Eric Horwitz; Thomas M Pisansky; Luis Souhami; Alan C Hartford; Michael Dominello; Felix Feng; Howard M Sandler Journal: Radiother Oncol Date: 2019-09-17 Impact factor: 6.280
Authors: Michael Behring; Kevin Hale; Bunyamin Ozaydin; William E Grizzle; Stephen O Sodeke; Upender Manne Journal: Cancer Date: 2019-09-10 Impact factor: 6.860
Authors: Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Veit Sandfort; Sanjeewani T Palayoor; Barbara H Rath; Lance Liotta; Mariaelena Pierobon; Emanuel F Petricoin; Matthew F Brown; Jayne M Stommel; Mansoor M Ahmed; C Norman Coleman Journal: Mol Cancer Ther Date: 2017-08-11 Impact factor: 6.009
Authors: Seth A Rosenthal; Chen Hu; Oliver Sartor; Leonard G Gomella; Mahul B Amin; James Purdy; Jeff M Michalski; Mark G Garzotto; Nadeem Pervez; Alexander G Balogh; George B Rodrigues; Luis Souhami; M Neil Reaume; Scott G Williams; Raquibul Hannan; Eric M Horwitz; Adam Raben; Christopher A Peters; Felix Y Feng; William U Shipley; Howard M Sandler Journal: J Clin Oncol Date: 2019-03-12 Impact factor: 50.717